The fresh funds will be used to expand clinics, invest in AI-driven healthcare, and enhance patient engagement, strengthening ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) yesterday. The company’s shares ...

Sexual wellness startup Allo Health will use the capital to expand its clinic network, strengthen technological capabilities, ...

Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 28 ...

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line ...

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed ...

16 mars • Lancement de l’album « Les Échos », de Jeannine Guyot • Salle Antoine-Gaborieau 21 mars • Formation | Violence ...

Bengaluru-based Allo Health raises INR 16 Cr in Pre-Series A round led by Zerodha's Rainmatter to expand clinic network and ...

Allo Health raises Rs. 16 crore to expand India’s largest sexual health ecosystem: Our Bureau, Bengaluru Wednesday, March 12, 2025, 17:45 Hrs [IST] Allo Health, India’s leadin ...

Seres has submitted clarification questions to FDA and expects a response in the coming weeks, which will inform the proposed ...

Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases. Read why I'm bullish on ALLO stock.

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...